Denali Therapeutics Inc. (DNLI) Current Ratio
- Current ratio · latest quarter: Value 8.37×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.37× | Current assets / current liabilities. $753.93M ÷ $90.08M ≈ 8.37× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 753.93M USD | Assets, Current |
| Current obligations | 90.08M USD | Liabilities, Current |
| Cash and equivalents | 201.53M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 508.94M USD | Marketable Securities, Current |
| Customer receivables | 3.93M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 4.14M USD | Inventory, Net |
| Payables | 11.81M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $753.93M | $90.08M | $201.53M | $508.94M | $3.93M | $4.14M | $11.81M | (m) | 8.37× |
| 2026-03-31 | $1.02B | $110.16M | $387.63M | $600.06M | (m) | (m) | $40.38M | (m) | 9.28× |
| 2025-12-31 | $900.66M | $98.35M | $205.33M | $662.55M | $0.00 | $0.00 | $505.00K | (m) | 9.16× |
| 2025-09-30 | $882.60M | $90.15M | $90.96M | $757.24M | (m) | (m) | $6.75M | (m) | 9.79× |
| 2025-06-30 | $934.71M | $91.06M | $141.21M | $757.75M | (m) | (m) | $10.84M | (m) | 10.27× |
| 2025-03-31 | $878.64M | $91.88M | $56.95M | $760.98M | (m) | (m) | $8.46M | (m) | 9.56× |
| 2024-12-31 | $864.44M | $102.21M | $174.96M | $657.37M | (m) | (m) | $11.14M | (m) | 8.46× |
| 2024-09-30 | $868.84M | $87.09M | $90.64M | $745.92M | (m) | (m) | $9.59M | (m) | 9.98× |
| 2024-06-30 | $928.38M | $74.53M | $74.68M | $821.37M | (m) | (m) | $13.94M | (m) | 12.46× |
| 2024-03-31 | $973.58M | $82.58M | $60.57M | $876.29M | (m) | (m) | $11.86M | (m) | 11.79× |
| 2023-12-31 | $1.06B | $77.98M | $127.11M | $907.40M | (m) | (m) | $9.48M | (m) | 13.65× |
| 2023-09-30 | $1.14B | $71.18M | $148.01M | $961.25M | (m) | (m) | (m) | (m) | 16.06× |
| 2023-06-30 | $1.22B | $69.36M | $131.97M | $1.06B | (m) | (m) | (m) | (m) | 17.65× |
| 2023-03-31 | $1.33B | $391.08M | $68.13M | $1.22B | (m) | (m) | (m) | (m) | 3.39× |
| 2022-12-31 | $1.37B | $363.92M | $218.04M | $1.12B | (m) | (m) | $2.79M | (m) | 3.77× |
| 2022-09-30 | $1.14B | $360.67M | $118.61M | $987.44M | (m) | (m) | $7.54M | (m) | 3.16× |
| 2022-06-30 | $1.11B | $348.16M | $155.09M | $913.58M | (m) | (m) | $7.12M | (m) | 3.20× |
| 2022-03-31 | $988.44M | $341.24M | $104.95M | $852.57M | (m) | (m) | $3.36M | (m) | 2.90× |
| 2021-12-31 | $897.23M | $378.25M | $293.48M | $571.93M | (m) | (m) | $4.78M | (m) | 2.37× |
| 2021-09-30 | $1.06B | $54.25M | $394.55M | $644.62M | (m) | (m) | $4.82M | (m) | 19.46× |
| 2021-06-30 | $1.34B | $51.41M | $485.68M | $823.25M | $15.22M | (m) | $4.24M | (m) | 26.10× |
| 2021-03-31 | $1.43B | $54.61M | $435.32M | $977.83M | (m) | (m) | $1.63M | (m) | 26.22× |
| 2020-12-31 | $1.50B | $71.70M | $507.14M | $962.55M | (m) | (m) | $1.07M | (m) | 20.86× |
| 2020-09-30 | $970.87M | $105.41M | $351.05M | $610.15M | (m) | (m) | $2.81M | (m) | 9.21× |
| 2020-06-30 | $559.41M | $58.46M | $137.18M | $412.40M | (m) | (m) | $1.87M | (m) | 9.57× |
| 2020-03-31 | $604.78M | $47.63M | $207.54M | $379.71M | (m) | (m) | $2.32M | (m) | 12.70× |
| 2019-12-31 | $430.03M | $45.34M | $79.45M | $335.91M | (m) | (m) | $2.59M | (m) | 9.48× |
| 2019-09-30 | $494.38M | $46.69M | $82.67M | $396.72M | (m) | (m) | $2.02M | (m) | 10.59× |
| 2019-06-30 | $495.98M | $46.55M | $62.94M | $415.67M | (m) | (m) | $3.93M | (m) | 10.66× |
| 2019-03-31 | $499.53M | $43.24M | $39.66M | $445.82M | (m) | (m) | $3.66M | (m) | 11.55× |
| 2018-12-31 | $480.84M | $32.79M | $77.12M | $387.17M | (m) | (m) | $1.89M | (m) | 14.67× |
| 2018-09-30 | $383.40M | $31.62M | $43.65M | $331.31M | (m) | (m) | $3.35M | (m) | 12.13× |
| 2018-06-30 | $377.42M | $31.01M | $33.09M | $339.50M | (m) | (m) | $9.18M | (m) | 12.17× |
| 2018-03-31 | $377.42M | $17.17M | $44.00M | $329.40M | (m) | (m) | $1.38M | (m) | 21.99× |
| 2017-12-31 | $409.61M | $14.16M | $218.38M | $187.85M | (m) | (m) | $2.72M | (m) | 28.92× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |